Announced Fri, 19 Jun · 17:25 IST
Albert David appoints Amit Mahla as Whole-time Director and CEO for 5 years
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.5%1-day move
₹710.50
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+0.5+0.2-0.7-0.4-1.8+0.9-2.2-3.3——
Up moveDown movePending
AI summary
Albert David's Board has appointed Mr. Amit Mahla (DIN: 11767012) as Additional Director and Whole-time Director and CEO for 5 years from June 19, 2026 to June 18, 2031. He was already serving as CEO since May 12, 2026. Mr. Mahla, aged 52, has over 28 years of pharma experience across Cipla, Emcure, Glenmark, Alembic, Sun Pharma, and JB Pharma. He is not related to any existing director or KMP and his appointment is subject to shareholder approval at the 87th AGM.
Likely market impact
Formalizes CEO role with a seasoned pharma industry veteran. Appointment needs shareholder nod at 87th AGM; remuneration fixed till March 31, 2027.